Intracellular and Extracellular Labile Iron Pools

  • Z. Ioav Cabantchik
  • Or Kakhlon
  • Silvina Epsztejn
  • Giulianna Zanninelli
  • William Breuer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 509)

Abstract

Labile forms of iron present in biological systems are defined as ionic Fe complexes that are redox active. They comprise a heterogeneous population of organic anions (phosphates and carboxylates), poly-functional ligands (i.e. chelates, siderophores and polypeptides) or surface components of membranes (e.g. phospholipid head groups) or extracellular matrix (e.g. glycans and sulfonates), which bind both forms of iron (II and III). Collectively, they define the respective labile iron pools (LIP), which can be of cellular (CLIP) or extracellular (ECLIP) nature. Operationally, those pools are characterized in terms of their propensity to engage in redox-cycling in an oxygenated environment and/or following pro-oxidant challenges. Methodologically, CLIP and ECLIP can be assessed in terms of iron reactivity and/ or the ability of the metal to undergo chelation by high affinity binding siderophores or chelators. Therapeutically, the LIPs are the immediate targets of chelators designed to reduce iron load in the entire organism, with emphasis on organs of accumulation such as the liver.

Keywords

Anemia Polypeptide Oxalate Turbidity Fluorescein 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Crichton, R.R. (1991). Inorganic Biochemistry of Iron Metabolism. New York, London, Toronto, Sydney, Tokyo, Singapore, Ellis HorwoodGoogle Scholar
  2. 2.
    Epaztejn, S., Kakhlon, O., Breuer, W. Gliokstein, H. and Cabantohilc, Z.I.,(1997) A fluorescence assay for the labile iron pool (LIP) of mammalian cells.Anal. Biochem. 248: 31–40.CrossRefGoogle Scholar
  3. 3.
    Breuer, V.W., Epstejn, S., Milgram, P. and Cabantchdc, Z.I. (1995). Transport of iron and other related metals into cells as revealed by a fluorescent probe.Am. J. Phyaiol (Cell)268: 1354–1361.Google Scholar
  4. 4.
    Breuer, W., Epstejn, S, and Cabantchik, Z.I. (1995). Iron acquired from transfenin by K562 cells is delivered into a oytoplasmic pool of chelatable iron(II).J. Biol. Chem. 270: 24209–24215CrossRefGoogle Scholar
  5. 5.
    Jacobs, A. (1977) An intracellular transit iron pool.Blood50: 4331–4336.Google Scholar
  6. 6.
    Kozlov, A.V., Yegorov, D.Y., Vladimirov, Y.A. and Azizova,O.A. (1992). Intracellular iton in liver tissue and liver homegenatc-tudies with electron paramagnetic resonance onthe formation of paramagnetic complexes with desfecal and nitric oxide.Free Rad BioL Med13: 9–16.CrossRefGoogle Scholar
  7. 7.
    Rothman, R. J., Serroni, A. and Farber, J. L. (1992). Cellular pool of transient ferric iron, ohelatable by deferoxamine and distinct front Ft, that is involved in oxidative cell injury.MoL PharmacoL42: 703–710Google Scholar
  8. 8.
    Eisenstein, RD. (2000) Iron regulator proteins and the molecular control of mammalian iron metabolism Annu Rev.Nutr.20:627–62Google Scholar
  9. 9.
    Aisen P, Wessling-Resnick M, Leibold EA. Iron metabolism (1999). Cues Opin Chem Bio13:200–6Google Scholar
  10. 10.
    Hershko H, Graham G, Bates GW, Rachmilewitz E: Nonspecific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Brit. J. Haematol. 1978; 40: 255–263.CrossRefGoogle Scholar
  11. 11.
    Graham G, Bates GW, Rachmilewitz EA, Hershko C: Nonspecific serum iron in thalassemia: quantitation and chemical reactivity. Am. J. Hematol. 1979; 6:207–217.CrossRefGoogle Scholar
  12. 12.
    Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S: Kinetios of removal and reappearance of non-transfe inbound pluma iron with deferoxamine therapy. Blood 1996; 88:705–13.Google Scholar
  13. 13.
    Batey RG, Lai Chung Fong P, Shamir S, Sherlock S: A non-transfer in-bound serum iron in idiopathic hemochromatosis. Dig Dis Sci. 1980; 25:340–6.CrossRefGoogle Scholar
  14. 14.
    Aruoma OI, Bomford A, Polson RJ, Halliwell B: Nontransfenin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy. Blood 1988; 72:1416–9.Google Scholar
  15. 15.
    Loral D, Gosriwatana I, Guyader D, Porter J, Brissot P, Hider RC: Determination of non-tranaferrin-bound iron in genetic hemochromatosis using a new HPLC-baud method. J Hepatol. 2000; 32:727–33.CrossRefGoogle Scholar
  16. 16.
    Brauer W, Hershko C, Cabantchik ZL (2000) The importanoe of non#anaferrin iron in disorder of iron metabolism. Transfusion Soi. 2000; 23: 185–92.CrossRefGoogle Scholar
  17. 17.
    Gosriwatana 1, Loreal O, Lu S, Brissot P, Porter J, Hider RC: Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999; 273:212–20.CrossRefGoogle Scholar
  18. 18.
    Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI: The assessment of serum nontransferrinbound iron in ohelation therapy and iron supplementation. Blood. 2000; 95:2975–82.Google Scholar
  19. 19.
    Breuer W, Eimers, MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI: Desferrioxamine-dtdatabk iron (DCI), a component durum non-transferrin bound iron (NTBI) used for assessing ahelation therapy. Blood. 97:792–8.Google Scholar
  20. 20.
    Halliwell B, Gutteridge JM: Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186:1–85.CrossRefGoogle Scholar
  21. 21.
    Wright TL, Brissot P, Ma WL, Weisiger RA: Characterization of non-transferrin-bound iron clearance by rat liver. J Bid Chem. 1986; 261:10909–14.Google Scholar
  22. 22.
    Kaplan J, Jordan I, Sturrock A: Regulation of the transferrin-independent iron transport system in cultured cells. J Biol Chem. 1991; 266:2997–3004Google Scholar
  23. 23.
    Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Oliviori NF, Raohmilewitz EA, Hebbel RP.1995. Deferiprone (Ll) chelates pathologic iron deposits from membranes of intact thalassanic and sickle red blood cells both in vitro and in vivo. Blood. 86:2008–13Google Scholar
  24. 24.
    Cabantohik ZI, Breuer W, Slotki I, Beaumont C. (2001) Development and application of novel fluorescent assays for probing labile iron pools in biological systems. In: Badman DG, Bergeron RJ, Britt:sham GM, eds.Iron Chelators: New development strategies. Ponto Veda’, FL: The Saratoga Group; 2000:353–383.Google Scholar
  25. 25.
    Tsien, R. Y. (1989) Fluorescent probes of cell signaling.Ann.Rev. Neuroaci. 12: 227–53CrossRefGoogle Scholar
  26. 26.
    Ramachandram, B. and A. Samanta, A.1998. How important is the quenching influence of the transition metal ions in the design of fluorescent PET sensors? Chemical Physics Letters 290: 9–16CrossRefGoogle Scholar
  27. 27.
    Lytton, S.J., Mesta, B., Libman, J., Shanzer, A. and Cabentchik, Z.I.. (1992). Monitoring of iron(III) removal from biological sources using a novel fluorescent siderophore.Anal. Biochem. 205: 326–333CrossRefGoogle Scholar
  28. 28.
    Worts, M.ILV., Hofstraat, J.W., Gauls, F.A.J., and Verhoeven, J.W. 1997 Fluorescein and eosin as sensitizing ahromophores in near-infrared luminescent ytterbium(III), neodymium(III) and Terbium(III) chelates Chemical Physics Letters 276:196–201Google Scholar
  29. 29.
    Breuer W and Cabantohik ZI. (2001) A fluorescence based one-step assay for serum non-tranaferrin bound iron (NTBI).Anal. Biochem. (submitted).Google Scholar
  30. 30.
    Ramachandram, B. and A. Samanta, A.1998. Transition Metal Ion Induced fluorescence Enhancement of 4-(N, NDimethylethylenediamino)- 7- nitrobenz- 2- oxa- 1,3- diazoleJ. Phys. Chem. 102: 10579–10587.Google Scholar
  31. 31.
    Petrat F, Rauen U, de Groot H. 1999. Determination of the chelatable iron pool of isolated rat hepatocytes by digital fluorescence microscopy using the fluorescent probe,phen green SK.Hepatology. 29:1171–9.Google Scholar
  32. 32.
    Thomas F, Serratrice G, Beguin C, Aman ES, Pierre JL, Fontecave M, Laulhere JP. 1999 Calcein as a fluorescent probe for ferric iron. Application to iron nutrition in plant cells.J Biol Chem. 274:13375–83Google Scholar
  33. 33.
    Staubli A, Boelsterli UA 1998.The labile iron pool in hepatocytes: prooxidant-induced increase in free iron precedes oxidative cell injury Am J Physiol. 274:G1031–7.Google Scholar
  34. 34.
    Epsztejn, S. Picard. V, Breuer, W.V., Glickstein, H. Slotki, I.N., Beaumont C. and Cabantchik, Z.I. (1999). Functional consequences of H-ferritin over-expression in transfected cells.Blood94:3593–3603..Google Scholar
  35. 35.
    Richardson, D.R. and Ponka, P. 1997 The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells.Biochim. Beophys Acta. 1331: 1.40Google Scholar
  36. 36.
    Cabantchik, Z.I., Milgram, P., Glikhstkin, H. and Breuer, W., (1995) A method for assessing iron chelation in membrane model systems and in living mammalian cells.AnaL Biochem. 233: 221–227.CrossRefGoogle Scholar
  37. 37.
    Zanninelli, G., Brissot, P., Hider, RR., Konijn, A.P., Shama, A. and Cabantchílc, Z.L (1997). Chelation and mobilization of cellular iron by different classa of iron chelaton. MoLPharmacoL51: 842–852.Google Scholar
  38. 38.
    Bevilacqua, M.A., Faniello, M.C., Quaresima, B., Tiano, M.T., Giuliano, P., Feliciello, A., Avvedimento, V.E., Cimino, F. & Costanzo, F. (1997) A oommon mechanism underlying the E1A agression and the °AMP stimulation °f the H fa kin transcription.JBioLChem272: 20736–20741Google Scholar
  39. 39.
    Bevilaoqua, M A, Faniello, M.C, Russo, T., Cimino, F. & Castanzo, F. (1998) P/CAF/p300 complex binds the promoter for the heavy subunit of ferritin and contributes to ib tissue-specific expression.BiochemJ335: 521–525Google Scholar
  40. 40.
    Fuhrmann, G., Rosenberger, G., Causch, M., Klein, N., Hofmann, J. & Krupp G. (1999) The MYC dualism in growth and death.MutatRes. 437: 205–217Google Scholar
  41. 41.
    Tsuji, Y., Kwak, E., Seiko, T., Tati, S.V. & Tati, F.M. (1993) Preferential repression of the H subunit of ferritin by adawovirus E1 A in NIH-3T3 mouse fibroblasts.J.BioLChem. 268: 7270–7275Google Scholar
  42. 42.
    Tsuji, Y., Akebi, N., Lam, T.K., Nakabeppu, Y., Tati, S.V. & Tord, F.M. (1995) FER-1, an enhancer of the ferritin H gare and a target of El A-mediated transcriptional repression.MoLCell BioL15: 5152–5164Google Scholar
  43. 43.
    Tsuji, Y., Moran, E., Torii, S.V. & Torti, F.M. (1999) Transcriptional regulation of the mouse faritin H gene. Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity.JBioLChem274: 7501–7507Google Scholar
  44. 44.
    Wu, K.J, Polack, A&Dalla Favors, R. (1999) Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by o-MYC.Science283: 676–679CrossRefGoogle Scholar
  45. 45.
    Pinero, D.J., Hu, J., Cook, B.M., Scaduto, RC. & Connor, J.R. (2000) Interleukin-lbda increases binding of the iron regulatory protein and the synthesis of ferritin by increasing the labile iron pool.Biochim.BiophysActa1497: 279288Google Scholar
  46. 46.
    Picard, V., Renaudie, F., Porcher, C., Henke, M.W., Grandchamp, B. & Beaumont, C. (1996) Ove expression tithe ferritin H subunit in cultured erythroid cells changes the intracellular iron distribution.Blood87: 2057–2064Google Scholar
  47. 47.
    Picard, V., Epztejn, S., Santambrogio, P., Cabantchik, Z.I. & Beaumont, C. (1998) Roleoffaritin in the control of the labile iron pod in murine erythroleukemia cells.J.BioLChem. 273:15382–15386Google Scholar
  48. 48.
    Cozzi, A., Corsi, B., Levi S, Santambrogio, P., Albertini, A. & Araio, P. (2000) Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase aotivity.J.BioLChem. 275: 2512225129Google Scholar
  49. 49.
    Kakhlon, A., Gruenbeum, Y. & Cabantchik, Z.I (2001) Repression of ferritin expression increases the labile iron pool, oxidative stress, and short term growth of human erythroleukemia oells.Blood97: 2863–2871.CrossRefGoogle Scholar
  50. 50.
    Kakhlon O, Gruenbaum Y, Cabantohik ZI. (2001) Repression of the heavy ferritin chain increases the labile iron pool of human K562 cells.Biochem J. 2001 Jun 1;356 (Pt 2):311–316.CrossRefGoogle Scholar
  51. 51.
    Tilbrook, G.S. and Hider, R.C. Iron chelaten for clinical use. In: Sigel, A. and Sigel, IL, eds.Metal Ions in Biological System’s: Iron Transport and Storage in Microorganisms Planer and Animals. 1998;Vol. 35:691–730. Marcel Dekker, New Yak.Google Scholar
  52. 52.
    Pollack S, Aisen P, Lasky FD, Vanderhoff G. (1976) Chelate mediated transfer of iron from transferrin to desfenicxamine.BrJ Haematol. 34:231–5.CrossRefGoogle Scholar
  53. 53.
    Pollack, S., Vanderhoff G. and Lasky, F. (1977) Iron removal from transferrin-an experimental study.Biochim. Brophy:. Acta497: 481–487.Google Scholar
  54. 54.
    Kontoghiorghes, G.J. (1995) New concepts of iron and aluminium °halation therapy with oral LI (Deferiprone) and other chelators.Analyst120:845–851.CrossRefGoogle Scholar
  55. 55.
    Aisen P, Leibman A, Zweier J. (1978) Stoichiometric and site characteristics of the binding of iron to human transferrin.JBiol Chem. 253:1930–7.Google Scholar
  56. 56.
    Evans, KW., Sharma, M., Ogwang, W., Patel, K.J., Bartlett, A.N. and Kontoghiorghes. (1992) The effect of alphaketo hydropyridine ohelakes on transfe ria saturation in vitro and in vivo.Drugs ofToday;28 (Suppl. A):19–23.Google Scholar
  57. 57.
    Wang WC, Ahmed N, Hanna M. J.Pediatr(1986) 108:552–7 Nor-tranafarm-bound iron in long-term transfusion in children with congenital anemias.Google Scholar
  58. 58.
    Ahmed NK. Hanna M. Wang W. (1986) Nontransferrin-bound serum iron in thalassemia and sickle cell patients.Intern. J. Biochem. 18:953–956.CrossRefGoogle Scholar
  59. 59.
    Araujo A, Kosaryan M, MaDDowell A, Wickens D, Puri S, Wonke B, Hoñbrand AV. (1996) A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload.BrJHaematol;93:835–7.CrossRefGoogle Scholar
  60. 60.
    al-Refaie FN., Wickens, DG., Wonke ,B. Kontoghiorghes GJ. and Hofbrand AV. (1992). Serum non-4ansfe inbound iron in beta4halassaemia major patients treated with desferrioxamine and L1.Brit. J. Haematol. 82:431–436.CrossRefGoogle Scholar
  61. 61.
    Wonke, B., Wright, C. and Hofbrand, kV. (1998) Combined therapy with defertprone and desferrioxamine.Br. J. Haematol. 103:361–4.CrossRefGoogle Scholar
  62. 62.
    Grady, R W., Berdoukas, V.A., Rachmilewitz, E.A. and Giardina, P.I. Combining deferiprone and desferrioxamine to optimize chdation. 10aInternational Conference on Oral Chelators, Limassol, Cyprus, Mar.22–26, 2000.Google Scholar
  63. 63.
    Grady, kW. and Giardina, P.J. Iron Chelation: Rationale for combination therapy. In: Badman, D.G., Bergeron, R.J. and Brittenham, G.M. eds.Iron Chelators: New development strategies. 2000; 293–310. The Saratoga Group, Ponte Ved., FL.Google Scholar
  64. 64.
    Singh, S., Hider, R.C. and Porter, J.B. (1990) A direct method for quantification of non-transferrin-bound iron.Anal Biochem. 186:320–323.CrossRefGoogle Scholar
  65. 65.
    Evans, PJ, Halliwell, B. (1994). Measurement of iron and copper in biological systems: bleomycin and copperphenanthroline assays.Meth. Enzymol. 233:82–89.CrossRefGoogle Scholar
  66. 66.
    Scheiber B, Goldenberg H. (1998). The surface of rat hepatocytes can transfer iron from stable ohelates to external acceptors.Hepatology. 27:1075–80.CrossRefGoogle Scholar
  67. 67.
    long TC, Deugnier Y, Halliday JW, Powell LW, Brissot P. (1997). Ultrastructural sequences during liver iron overload in genetic hemochromatosis.J. Hepatol. 27:628–38.CrossRefGoogle Scholar
  68. 68.
    Simpson RJ, Dee nmamode J, McKie AT, Raja KB, Salisbury JR, Iona TC, Peters TJ. (1997): Time-course of iron overload and biochemical, histopathological and ultrastructural evidence of pancreatic damage inhypotransferrina micmice. Clin. Sct (Cokh). 93:453–62.Google Scholar
  69. 69.
    Moura E, Noardc me er MA, Verhoeven N, Verheul AF, Marx JI. (1998). Iron release from human monocytes after e ythrophagocytosis in vitro: an investigation in normal subjects and hereditary hemochromatosis patients.Blood. 92:2511–9.Google Scholar
  70. 70.
    Grootveld, M, Bell, J.D., Halliwell, B., Aruoma, O.I., Bomfard, A. and Sadler, P.J. (1989) Non4ransferrin bound iron in plasma or serum from patients with idiopathic hemochromatosis.J. Biol. Chem. 264:4417–22.Google Scholar

Copyright information

© Kluwer Academic/Plenum Publishers, New York 2002

Authors and Affiliations

  • Z. Ioav Cabantchik
    • 1
  • Or Kakhlon
    • 1
  • Silvina Epsztejn
    • 1
  • Giulianna Zanninelli
    • 1
  • William Breuer
    • 1
  1. 1.Alexander Silberman Institute of Life SciencesHebrew UniversityJerusalemIsrael

Personalised recommendations